We serve Ethyl 6,8-dichlorooctanoate CAS:1070-64-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
| Items of Analysis | Standard of Analysis | Test Results |
| Appearance | Colourless or yellowish liquid | Conform |
| Related Substances | Max Individual impurity: ≤2.0% | 1.64% |
| Total impurity: ≤5.0% | 2.96% | |
| Residual Solvents | Toluene: ≤0.1% | ND |
| Purity（GC） | ≥95.0%（Qualified Product） ≥ 97.0%（Remium Grade） |
97.04% |
| Conclusion | Conforms to Factory Standard | |
Contact us for information like Ethyl 6,8-dichlorooctanoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6,8-Dichloro ethyl caprylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,OCTANOIC ACID,6,8-DICHLORO-,ETHYL ESTER Use and application,6,8-Dichlor-octansaeure-ethylester technical grade,usp/ep/jp grade.
Related News: Pharmaceutical intermediates and APIs belong to the fine chemical industry.2H-Naphtho[1,8-bc]furan, 2a,3,4,5-tetrahydro- manufacturer “So far, the finding is still under preliminary study, and a large number of experiments is needed to test if it is effective on patients,” it said, citing the WHO in saying that no proven effective drugs to prevent or treat the Wuhan coronavirus are currently available.methyl 3-chloro-2-((6-chloropyridin-3-yl)methoxy)-5-((3,3-dichloroallyl)oxy)benzoate supplier “So far, the finding is still under preliminary study, and a large number of experiments is needed to test if it is effective on patients,” it said, citing the WHO in saying that no proven effective drugs to prevent or treat the Wuhan coronavirus are currently available.L-phenylalanyl-L-methionyl-L-isoleucyl-L-leucyl-L-alanyl-L-seryl-L-prolyl-L-arginyl-L-tyrosyl-L-valine vendor Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL.Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL.
